111In-pentetreotide and 123I-MIBG for detection and resection of lymph node metastases of a carcinoid not visualized by CT, MRI or FDG-PET

Simple item page
dc.contributor.authorYüksel, M
dc.contributor.authorEziddin, S
dc.contributor.authorLadwein, E
dc.contributor.authorHaas, S
dc.contributor.authorBiersack, HJ
dc.date.accessioned2024-06-12T11:03:44Z
dc.date.available2024-06-12T11:03:44Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractA patient with a history of a jejunal carcinoid and resection of liver metastases underwent CT, MRI and FDG-PET as well as somatostatin receptor scintigraphy using In-111-pentetreotide during follow-up. Octreoscan demonstrated one extrahepatic abdominal lesion with pathologic uptake, while the other imaging modalities failed to show a corresponding abnormality. For verification of this finding I-123-MIBG scintigraphy was performed. The MIBG scan confirmed the octreotide positive lesion and showed an additional abdominal lesion in the SPECT study. According to the scintigraphic results, radioguided surgery (RGS) was implemented using I-123-MIBG. This resulted in the intra-operative detection of two para- and pre-aortic lymph node metastases by the gamma probe and successful resection. An additional preaortal lymph node, suspicious by palpation, was also removed. Histopathology revealed metastases of a carcinoid tumor in all three specimens. In conclusion, the use of RGS facilitates successful removal of carcinoid metastatic lesions despite negative conventional imaging results. Secondly, I-123-MIBG scintigraphy may provide advantages over octreoscan for preoperative localization as well as radio-guided surgery of neuroendocrine metastatic lesions, if the involved site is located in proximity to highly octreotide-avid organs such as the kidneys or spleen.en_US
dc.identifier.doi10.1007/BF02985056
dc.identifier.endpage615en_US
dc.identifier.issn0914-7187
dc.identifier.issn1864-6433
dc.identifier.issue7en_US
dc.identifier.pmid16363628en_US
dc.identifier.scopus2-s2.0-31544442958en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage611en_US
dc.identifier.urihttps://doi.org/10.1007/BF02985056
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21772
dc.identifier.volume19en_US
dc.identifier.wosWOS:000233572600013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals Of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIn-111-Pentetreotideen_US
dc.subjectI-123-MIBGen_US
dc.subjectRadioguided Surgeryen_US
dc.subjectCarcinoid Metastasesen_US
dc.subjectNeuroendocrine Tumoren_US
dc.subjectSomatostatin Receptor Scintigraphyen_US
dc.subjectPositron-Emission-Tomographyen_US
dc.subjectNeuroendocrine Tumorsen_US
dc.subjectI-131 Metaiodobenzylguanidineen_US
dc.subjectGastrointestinal-Tracten_US
dc.subjectDiagnosisen_US
dc.subjectAnalogen_US
dc.subjectProbeen_US
dc.title111In-pentetreotide and 123I-MIBG for detection and resection of lymph node metastases of a carcinoid not visualized by CT, MRI or FDG-PETen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize